Rúben Ramos, he received his MSc degree in Pharmaceutical Sciences from the Faculdade de Farmácia da Universidade de Lisboa, Portugal, in 2008. In the same year he started working as a senior technician at the Research Institute for Medicines and Pharmaceutical Sciences (iMed.ULisboa), in the Metabolism and Genetics group. There he received training in the field of rare metabolic diseases, being especially involved in the diagnosis and follow-up of patients with inborn errors of metabolism disorders. In 2009 he started a second MSc degree, in Clinical Chemistry, in the Faculdade de Farmácia da Universidade de Lisboa. He graduated in 2013, under the supervision of Prof. Isabel Tavares de Almeida. His work, in collaboration with Prof. Cornelis Jakobs and Dr. Mirjam Wamelink from the Free University of Amsterdam, the Netherlands, allowed the characterization of a new metabolic disorder in the pentose phosphate pathway. In 2014 Rúben started his PhD studies in the department of Genetics at the University Medical Center Utrecht, under the supervision of Prof. Nanda Verhoeven-Duif and Dr. Judith Jans. His studies focused on understanding the intracellular metabolic consequences of vitamin B6 deficiency and on improving the diagnostic tools and treatment options of patients with vitamin B6 deficiency. Additionally, his work allowed the characterization of a new B6-responsive inborn error of metabolism: GOT2 deficiency. Rúben currently works as a senior research assistant in the department of Cell Metabolism at Memorial Sloan Kettering Cancer Center in New York, United States of America. His current field of research focuses on understanding the impact of the human intestinal microbiome and its metabolome on treatment-related complication and mortality of cancer patients that underwent allogenic hematopoietic stem cell transplantation (allo-HCT).